Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Tenet Healthcare (THC) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly & Co (LLY)
In a report released today, Emily Field from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $1400.00. The company’s shares closed last Monday at $967.93, close to its 52-week high of $972.53.
According to TipRanks.com, Field is a 3-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1260.70, representing a 31.3% upside. In a report issued on April 21, TipRanks – xAI also upgraded the stock to Buy with a $1029.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Tenet Healthcare (THC)
In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Tenet Healthcare, with a price target of $238.00. The company’s shares closed last Monday at $185.35.
According to TipRanks.com, CFA is ranked 0 out of 5 stars with an average return of
Tenet Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $254.13, implying a 40.5% upside from current levels. In a report issued on May 1, TipRanks – DeepSeek also upgraded the stock to Buy with a $200.00 price target.
Read More on LLY:
Disclaimer & DisclosureReport an Issue
- Eli Lilly tells RBC liver case ‘not reasonably related to Foundayo’
- Eli Lilly fears for Foundayo ‘unfounded,’ says Wolfe Research
- Eli Lilly falls after FDA reports death of patient taking Foundayo
- Evercore says report in FAERS has ‘potential to create confusion’ for Eli Lilly
- The Week That Was, The Week Ahead: Macro and Markets, May 3
